Physician profile
Jianjun Li
NPI 1437171683
$210,910.86
in general payments reported to CMS, 2019-2025
29 companies · $19K in 2025
The $19K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $23K · 2021: $26K · 2022: $24K · 2023: $29K · 2024: $29K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68K · Food and Beverage: $5,357 · Travel and Lodging: $2,478 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68,475.00 |
| Food and Beverage | $5,356.78 |
| Travel and Lodging | $2,478.27 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $154,035.31 | 2019-2025 | Epclusa, Vemlidy |
| Abbvie INC. | $53,033.77 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,071.18 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $541.36 | 2022-2025 | Tremfya, Stelara |
| Intra-Sana Laboratories | $483.24 | 2022-2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Pfizer INC. | $263.58 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $239.28 | 2021-2024 | Cobenfy |
| Intercept Pharmaceuticals, INC. | $150.91 | 2020-2025 | |
| Novo Nordisk INC | $141.78 | 2019-2025 | Wegovy |
| Merck Sharp & Dohme LLC | $125.00 | 2020 | |
| Madrigal Pharmaceuticals | $120.50 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $104.96 | 2021-2023 | |
| Shionogi INC | $74.06 | 2019 | |
| Phathom Pharmaceuticals, INC. | $67.84 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $59.14 | 2021-2024 | Sutab, Suflave |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $43.42 | 2023 | Zeposia |
| Allergan, INC. | $41.14 | 2019 | |
| Redhill Biopharma INC. | $37.02 | 2021 | |
| Vivus LLC | $36.72 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.93 | 2020 | |
| Ardelyx, INC. | $33.56 | 2023-2024 | Ibsrela |
| Agios Pharmaceuticals, INC. | $28.75 | 2025 | Pyrukynd |
| Aimmune Therapeutics, INC. | $28.25 | 2024 | |
| Concordia Pharmaceuticals INC. | $23.80 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.04 | 2025 | Iqirvo |
| Exact Sciences Corporation | $18.77 | 2023 | Cologuard Collection Kit |
| Medtronic, INC. | $18.62 | 2023 | Sinuva |
| Qol Medical, LLC | $16.98 | 2023 | Sucraid |
| Ironwood Pharmaceuticals, INC | $13.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jianjun Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.